



AlzChem Group AG

Andreas Niedermaier, CEO
Dr. Georg Weichselbaumer, CSO

May 6, 2021



DISCLAIMER



Cautionary note regarding forward-looking statements

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the AlzChem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, AlzChem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA

Analyst Presentation Q1/2021



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

HIGHLIGHTS

Excellent start to the year with record sales and strong results



Strong recovery in Creapure®, positive development in NITRALZ® and Perlka® business



Continued high demand in pharma applications (Bioselect® and DCD)




Challenging raw materials and logistics situation



Good recovery of steel and automotive business



Strong development of EBITDA, equity and equity ratio



Persistently challenging management of Covid-19 effects

Next growth step is prepared



~12 m€

INVESTMENT (Step II.)

The additional investment, which will come on stream on Q2 2021, will create profitable growth

In 2017, AlzChem decided to invest 7.2 million € (Step I.) into a first expansion of the NITRALZ® production plant in Trostberg (DE)

The expanded plant was commissioned in July 2019 and quickly reached nameplate capacity

Commissioning of third production line scheduled for Q2

ADDITIONAL DEMAND

New applications in pharmaceuticals

+50%

PRODUCTION CAPACITY

Increased production capacities for NITRALZ®

ANNUAL SALES POTENTIAL

> 10 m€ up to 20 m€, depending on product portfolio



Nitriles are used in automotive paints. The best-known pigment of these is definitely PR 254, Irgazine® Red.

It provided, for the first time, a non-toxic and lightfast alternative to Vermilion Red and later Cadmium Red.

Its use as an automotive paint for a very special car gave this red pigment its nickname - Ferrari Red.



Crops around the world are exposed to various types of damage and threats.

Our nitriles in agricultural products, such as special fungicides, insecticides, herbicides and biocides, support healthy plant growth.



We do not get the majority of our sun dose in a few weeks of vacation, but daily in everyday life.

For this reason, sun protection is indispensable to prevent skin cancer.

NITRALZ® serves here as UV absorber for sunscreens.



Our NITRALZ® products are used as raw materials for the production of various APIs (= active pharmaceutical ingredients), including the long-established drug group 'sartans' on the world market.

Sartans have a blood pressure lowering effect and are used in the treatment of cardiovascular and also kidney diseases. Our advanced distillation process provides us with a reliably high standard of quality and purity, which is essential for their use in active ingredients.

FINANCIAL OVERVIEW Q1/2021



Key figures

| AlzChem Group | Q1 2020 | Q1 2021 | yoy % |
|---------------------------|------------|------------|---------|
| SALES (in M€) | 94.7 | 104.3 | +10.1% |
| EBITDA (in M€) | 12.3 | 16.7 | +35.8% |
| EBITDA margin (in %) | 13.0% | 16.0% | +3.0 pp |
| Earnings per Share (in €) | 0.43 | 0.78 | +80.1% |

| SALES ANALYSIS | DELTA Q1 |
|-------------------|-------------|
|-------------------|-------------|

| | |
|----------|-------|
| Volume | 12.9% |
| Price | -0.4% |
| Currency | -1.6% |

COMMENTS

- Q1/2021 strong sales - Alzchem runs at high speed
- Main drivers are agriculture (early orders for Dormex® to avoid logistic bottlenecks), human nutrition (Creapure®) as well as pharma (DCD and Bioselect®)
- Exceptional EBITDA increase yoy
- But also considerable exchange rate pressure and highly volatile raw material markets

AGENDA

Analyst Presentation Q1/2021



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP




The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.


BASICS & INTERMEDIATES SEGMENT

Strong sales and EBITDA development


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q1 |
|----------|-------------|
| Volume | 15.0% |
| Price | -0.4% |
| Currency | -0.6% |

COMMENTS

- Q1/2021 sales significantly above previous year
- Continued high demand for Perlka®, Dicyandiamide, hot metal desulphurization as well as NITRALZ®.
- Production cost optimization can still compensate raw material cost increases, but raw material markets are highly volatile.
- Supply chains are negatively affected, but impacts can be traded within AlzChem
- Strong EBITDA increase due to larger sales volumes of high added value products

SPECIALTY CHEMICALS



The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

CREAMINO

DYHARD[®]

Bioselect[®]


Dormex[®]

Creapure[®]


SPECIALTY CHEMICALS SEGMENT

Positive development of sales and EBITDA


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q1 |
|----------|-------------|
| Volume | 12.0% |
| Price | -0.8% |
| Currency | -2.4% |

COMMENTS

- Close to all time high sales in Q1/2021; sales 8.8% above previous year level
- Still high demand for raw materials for the pharmaceutical industry (BioSelect®) and furthermore increasing Dietary Supplements (Creapure®) as well as Building Blocks demand.
- Strong Dormex® deliveries, even above a good Q1/2020
- Stable Creamino® deliveries at level of previous quarter
- Strong EBITDA increase due to volume recovery and rise in high-value products

OTHER & HOLDING




The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.


OTHER & HOLDING SEGMENT

Service sales on previous year level, but increase in EBITDA


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q1 |
|----------|-------------|
| Volume | -3.1% |
| Price | 2.3% |
| Currency | 0.0% |


COMMENTS

- Overall sales on previous year level
- Normalization of the purchasing behavior of the site customers in the direction of "pre-Corona level"
- EBITDA-Margin of 6.7% (previous year 4.9%)

BALANCE SHEET


Equity ratio increased significantly

ASSETS



- Other non-current assets almost on level of Q4/2020
- Positive impact from inventory optimization project
- Increase in trade receivables follows improved business performance


LIABILITIES



- Equity ratio increased from 19.4% to 22.8% (positive group net income for the period)
- Lower pension provision due to rising interest rates
- Lower other non-current liabilities because of regular repayment of long-term loans

CASHFLOW

Due to high capex, free cash flow temporarily slightly red




COMMENTS

- Net cashflow on previous year level
- Investing cashflow above Q1/2020 level mainly due to capital spending for NITRALZ® CAPEX project in Q1/2021
- Cashflow from financing activities (-4.1 M€) – main effects: scheduled repayment of bank loans (- 3.0 M€), repayment of lease liabilities (-0.5 M€) and payments for the acquisition of own shares (-0.5 M€)

IMPLEMENTING OPERATING TARGETS


Focus on key growth drivers, sustainability and pandemic management




OUTLOOK 2021

Good chances of reaching the forecast at the upper end

SALES



EBITDA



COMMENTS

- Further growth of NITRALZ® business
- Expansion of Creamino® business
- Reinforcement of custom manufacturing
- Stable development in the agriculture sector
- Focus on pharma raw materials (Bioselect®)
- Higher raw material prices impact earnings with beginning of Q2
- Assumption US dollar exchange rate: 1.18 €/US\$

FINANCIAL CALENDAR

Upcoming dates



| | | |
|------|--------------------|--|
| 2021 | MAY 12 | Annual General Meeting 2021 (virtual) |
| 2021 | MAY 17 – 19 | Virtual Spring Conference 2021 (virtual) |
| 2021 | AUG 5 | Half-Year Financial Report 2021 |
| 2021 | SEP 6 – 7 | Fall Conference 2021, Frankfurt |
| 2021 | SEP 21 + 23 | Baader Investment Conference |
| 2021 | SEP 22 | Berenberg and Goldman Sachs Tenth German Corporate Conference |
| 2021 | NOV 11 | Quarterly Statement 3 rd Quarter 2021 |
| 2021 | NOV 22 – 24 | Deutsches Eigenkapitalforum |
| 2021 | DEC 6 – 9 | Berenberg European Conference |
| 2021 | DEC 7 – 8 | MKK – Münchner Kapitalmarkt Konferenz |





1,631

EMPLOYEES
(PY ~1,627)

M€
~104
SALES
(PY ~95)

M€
~17
EBITDA
(PY ~12)


M€
~8
OPERATING
CASHFLOW
(PY ~8)



ALZCHEM
PRODUCTS
ARE SOLD
WORLDWIDE

INNOVATION SINCE

1908



*All financial indicators relating to
YTD 2021/03 figures and YTD PY*



THANK YOU
FOR YOUR ATTENTION!

CONTACT

Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

WWW.ALZCHEM.COM

AGENDA

Analyst Presentation Q1/2021



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BALANCE SHEET

AlzChem Group




| ALZCHEM GROUP (IN T€) | 31.12.2020 | 31.03.2021 | Deviation | |
|--|----------------|----------------|---------------|--------------|
| Intangible assets | 1,810 | 1,670 | -141 | -7.8% |
| Tangible assets | 175,062 | 175,052 | -11 | 0.0% |
| Investment properties | | | | |
| Right of use (assets) | 8,524 | 8,391 | -133 | -1.6% |
| Investments accounted for using the equity | | | | |
| Financials assets | 20 | 20 | 0 | 0.0% |
| Trade receivables | | | | |
| Other receivables | 630 | 630 | 0 | 0.0% |
| <i>there of Deferred tax assets for pensions</i> | | | | |
| Deferred tax assets | 35,795 | 33,026 | -2,769 | -7.7% |
| SUM NON-CURRENT ASSETS | 221,842 | 218,789 | -3,053 | -1.4% |
| Inventories | 67,402 | 66,160 | -1,242 | -1.8% |
| Trade receivables | 33,124 | 47,248 | 14,124 | 42.6% |
| Financial assets | 0 | | 0 | -100.0% |
| Other receivables | 13,501 | 14,775 | 1,274 | 9.4% |
| Income tax receivables | 1,311 | 954 | -357 | -27.3% |
| Cash and cash equivalents | 17,117 | 11,234 | -5,883 | -34.4% |
| Assets classified as held for sale | | | | |
| Other assets | | | | |
| SUM CURRENT ASSETS | 132,456 | 140,371 | 7,916 | 6.0% |
| SUM ASSETS | 354,298 | 359,160 | 4,862 | 1.4% |

| ALZCHEM GROUP (IN T€) | 31.12.2020 | 31.03.2021 | Deviation | |
|---|----------------|----------------|----------------|--------------|
| Share capital | 101,763 | 101,763 | | |
| RETAINED EARNINGS (+) / LOSS (-) | 81,356 | 89,243 | 7,887 | 9.7% |
| Other comprehensive income | -53,077 | -46,415 | 6,662 | -12.6% |
| Own shares | | -502 | -502 | |
| SHARE TO THE SHAREHOLDERS | 66,895 | 80,941 | 14,047 | 21.0% |
| Non-controlling interests | 1,763 | 1,806 | 43 | 2.4% |
| SUM EQUITY | 68,658 | 82,748 | 14,090 | 20.5% |
| Provisions for pensions | 141,775 | 132,911 | -8,863 | -6.3% |
| Other provisions | 24,233 | 24,018 | -215 | -0.9% |
| Loans | 48,042 | 45,094 | -2,949 | -6.1% |
| Finance lease liabilities | 6,680 | 6,211 | -470 | -7.0% |
| Other liabilities | 342 | 342 | | |
| Deferred tax liabilities | 4,695 | 4,781 | 86 | 1.8% |
| SUM NON-CURRENT LIABILITIES | 225,767 | 213,357 | -12,410 | -5.5% |
| Other provisions | 2,877 | 4,490 | 1,613 | 56.1% |
| Loans | 12,704 | 12,716 | 12 | 0.1% |
| Finance lease liabilities | 1,634 | 2,026 | 392 | 24.0% |
| Finance liabilities | 0 | 0 | 0 | <-1.000% |
| Trade liabilities | 20,880 | 21,281 | 401 | 1.9% |
| Other liabilities | 21,583 | 21,658 | 75 | 0.3% |
| Income tax liabilities | 193 | 884 | 691 | 357.0% |
| SUM CURRENT LIABILITIES | 59,872 | 63,056 | 3,183 | 5.3% |
| Sum EQUITY AND LIABILITIES | 354,298 | 359,160 | 4,862 | 1.4% |

PENSION ACCOUNTING (IFRS)

AlzChem Group (M€)



COMMENTS

- Adjustment of market interest rate from 0.50% → 0.80% decreased provision
- Slowly increasing cash payments

INCOME STATEMENT

AlzChem Group



| | 01.01.2020 - 31.03.2020 | 01.04.2020 - 30.06.2020 | 01.07.2020 - 30.09.2020 | 01.10.2020 - 31.12.2020 | 01.01.2021 - 31.03.2021 | 01.04.2021 - 30.06.2021 | 01.07.2021 - 30.09.2021 | 01.10.2021 - 31.12.2021 | | | | |
|--|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|------------------|----------------|----------------|------------------|
| ALZCHEM GROUP (IN T€) | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Deviation (Q1) | YTD Mrz. 20 | YTD Mrz. 21 | Dev. YOY |
| Revenue | 94,740 | 102,511 | 81,373 | 100,634 | 104,321 | | | | 9,582 10% | 94,740 | 104,321 | 9,582 10% |
| Increase (+) / Decrease (-) in inventories of finished goods | 2,152 | -3,162 | 3,295 | -4,800 | -2,144 | | | | -4,296 -200% | 2,152 | -2,144 | -4,296 90% |
| Other income | 2,425 | 2,648 | 2,732 | 2,866 | 3,983 | | | | 1,558 64% | 2,425 | 3,983 | 1,558 54% |
| Raw materials and consumables used | -35,491 | -35,253 | -29,903 | -31,860 | -36,226 | | | | -735 2% | -35,491 | -36,226 | -735 2% |
| Employee benefits expense | -32,509 | -31,733 | -29,033 | -34,133 | -33,038 | | | | -529 2% | -32,509 | -33,038 | -529 2% |
| Other expense | -19,002 | -18,190 | -16,477 | -20,024 | -20,175 | | | | -1,173 6% | -19,002 | -20,175 | -1,173 6% |
| EBITDA | 12,315 | 16,822 | 11,986 | 12,683 | 16,722 | | | | 4,407 36% | 12,315 | 16,722 | 4,407 35% |
| Depreciation expense | -5,582 | -5,742 | -5,669 | -6,104 | -5,771 | | | | -189 3% | -5,582 | -5,771 | -189 3% |
| Impairment | | | | | | | | | | | | |
| EBIT | 6,734 | 11,080 | 6,318 | 6,578 | 10,951 | | | | 4,217 63% | 6,734 | 10,951 | 4,217 64% |
| Investment income | 5 | 20 | 103 | 6 | 5 | | | | 0 -9% | 5 | 5 | 0 -8% |
| Other interest and similar income | 620 | -453 | 14 | 10 | 507 | | | | -113 -18% | 620 | 507 | -113 -1174% |
| Other interest and similar expense | -874 | -925 | -1,088 | -948 | -425 | | | | 449 -51% | -874 | -425 | 449 -47% |
| Financial result | -248 | -1,358 | -971 | -932 | 88 | | | | 336 -135% | -248 | 88 | 336 -36% |
| Result from associates | | | | | | | | | | | | |
| Result from ordinary business | 6,485 | 9,721 | 5,347 | 5,646 | 11,039 | | | | 4,553 70% | 6,485 | 11,039 | 4,553 81% |
| Taxes on income and profit | -2,063 | -2,970 | -1,542 | -759 | -3,109 | | | | -1,046 51% | -2,063 | -3,109 | -1,046 138% |
| <i>thereof income tax</i> | -1,630 | -3,300 | -1,241 | -814 | -2,737 | | | | -1,106 68% | -1,630 | -2,737 | -1,106 136% |
| <i>thereof change from deferred taxes</i> | -433 | 330 | -301 | 55 | -373 | | | | 60 -14% | -433 | -373 | 60 111% |
| Annual result | 4,422 | 6,752 | 3,805 | 4,887 | 7,930 | | | | 3,507 79% | 4,422 | 7,930 | 3,507 72% |
| <i>thereof minority interests</i> | 43 | 43 | 43 | 43 | 43 | | | | | 43 | 43 | |
| <i>thereof shares held by shareholders</i> | 4,380 | 6,709 | 3,762 | 4,844 | 7,887 | | | | 3,507 80% | 4,380 | 7,887 | 3,507 72% |
| Result per share in EUR | 0.43 € | 0.66 € | 0.37 € | 0.48 € | 0.78 € | | | | | 0.43 € | 0.78 € | |

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)

| | Q1 2020 | Q1 2021 | Deviation (QoQ) | | YTD Mrz.2020 | YTD Mrz.2021 | Deviation (YoY) | |
|---|---------------|---------------|-----------------|----------------|-----------------|-----------------|-----------------|----------------|
| Revenue | 94,740 | 104,321 | 9,582 | 10.1% | 94,740 | 104,321 | 9,582 | 10.1% |
| Increase (+) / Decrease (-) in inventories of finished goods and work in progress | 2,152 | -2,144 | -4,296 | -199.6% | 2,152 | -2,144 | -4,296 | -199.6% |
| Other income | 2,425 | 3,983 | 1,558 | 64.3% | 2,425 | 3,983 | 1,558 | 64.3% |
| Raw materials and consumables used | -35,491 | -36,226 | -735 | 2.1% | -35,491 | -36,226 | -735 | 2.1% |
| Employee benefits expense | -32,509 | -33,038 | -529 | 1.6% | -32,509 | -33,038 | -529 | 1.6% |
| Other expense | -19,002 | -20,175 | -1,173 | 6.2% | -19,002 | -20,175 | -1,173 | 6.2% |
| EBITDA | 12,315 | 16,722 | 4,407 | 35.8% | 12,315 | 16,722 | 4,407 | 35.8% |
| Depreciation expense | -5,582 | -5,771 | -189 | 3.4% | -5,582 | -5,771 | -189 | 3.4% |
| Impairment | 0 | 0 | 0 | | 0 | 0 | 0 | |
| EBIT | 6,734 | 10,951 | 4,217 | 62.6% | 6,734 | 10,951 | 4,217 | 62.6% |
| Investment income | 5 | 5 | 0 | -8.6% | 5 | 5 | 0 | -8.6% |
| Other interest and similar income | 620 | 507 | -113 | -18.2% | 620 | 507 | -113 | -18.2% |
| Other interest and similar expense | -874 | -425 | 449 | -51.4% | -874 | -425 | 449 | -51.4% |
| Financial result | -248 | 88 | 336 | -135.3% | -248 | 88 | 336 | -135.3% |
| Result from associates | 0 | 0 | 0 | | 0 | 0 | 0 | |
| Result from ordinary business | 6,485 | 11,039 | 4,553 | 70.2% | 6,485 | 11,039 | 4,553 | 70.2% |
| Taxes on income and profit | -2,063 | -3,109 | -1,046 | 50.7% | -2,063 | -3,109 | -1,046 | 50.7% |
| <i>thereof income tax</i> | -1,630 | -2,737 | -1,106 | 67.9% | -1,630 | -2,737 | -1,106 | 67.9% |
| <i>thereof change from deferred taxes</i> | -433 | -373 | 60 | -13.9% | -433 | -373 | 60 | -13.9% |
| Annual result | 4,422 | 7,930 | 3,507 | 79.3% | 4,422 | 7,930 | 3,507 | 79.3% |
| <i>thereof minority interests</i> | 43 | 43 | 0 | 0.0% | 43 | 43 | 0 | 0.0% |
| <i>thereof shares held by shareholders</i> | 4,380 | 7,887 | 3,507 | 80.1% | 4,380 | 7,887 | 3,507 | 80.1% |
| Result per share in EUR | 0.44 € | 0.78 € | 0 | 79.3% | 0.44 € | 0.78 € | 0 | 79.3% |

CASH FLOW

AlzChem Group



CASHFLOW (IN M€)

| | Q1 2020 | Q1 2021 |
|--|---------------|---------------|
| Consolidated earnings before taxes | 6,485 | 11,039 |
| Depreciation on fixed and intangible assets | 5,582 | 5,771 |
| Decrease in pension provisions | -378 | -420 |
| Loss (+) / Profit (-) from the sale of non-current assets | -1 | -2 |
| Other non-cash income (-) and expenses (+) | 1,155 | 3,980 |
| Financial result | 248 | -88 |
| Interests & Taxes | -1,839 | -1,782 |
| Increase (+) / Decrease (-) Net Working Capital | -2,776 | -10,408 |
| Cashflow from ongoing operations (Net cash flow) | 8,477 | 8,091 |
| Cash outflows for investments in fixed assets | -4,810 | -9,994 |
| Cash inflows from the sale of fixed assets | 1 | 8 |
| Cash inflow from the acquisition / Reverse acquisition | | |
| Cashflow from investing activity | -4,810 | -9,986 |
| Free cashflow | 3,667 | -1,896 |
| Deposits (+) / Repayment (-) bank loans long-term | | |
| Repayment of bank loans long-term | -2,016 | -2,984 |
| Deposits (+) / Repayment (-) from short-term financing lines | -1 | |
| Dividend payments | | |
| Payment of reduction in leasing liabilities | -470 | -456 |
| Payments for the acquisition of own shares (incl. transaction costs) | | -503 |
| Payments to non-controlling interests | -171 | -171 |
| Cashflow from financing activity | -2,657 | -4,114 |
| Net increase / decrease in cash and cash equivalents | 1,010 | -6,010 |

SEGMENT OVERVIEW BY QUARTER

AlzChem Group



| SALES | 2019 | | | | 2020 | | | | 2021 | | | | Deviation PY (Q1) | | YTD Q1 2021 | | Deviation PY (YOY) | |
|------------------------|---------------|---------------|---------------|---------------|---------------|----------------|---------------|----------------|----------------|----------|----------|----------|-------------------|-----------|---------------|----------------|--------------------|------------|
| | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | | | PY T€ | Actual T€ | | |
| Basics & Intermediates | 35,465 | 37,844 | 41,693 | 34,405 | 36,012 | 38,266 | 32,320 | 39,837 | 41,070 | | | | 5,058 | 12% | 36,012 | 41,070 | 5,058 | 14% |
| Specialty Chemicals | 50,063 | 51,686 | 50,952 | 47,321 | 52,199 | 57,854 | 42,995 | 54,383 | 56,775 | | | | 4,576 | 8% | 52,199 | 56,775 | 4,576 | 9% |
| Other and Holding | 6,595 | 6,591 | 6,786 | 6,672 | 6,529 | 6,391 | 6,058 | 6,414 | 6,477 | | | | -52 | -1% | 6,529 | 6,477 | -52 | -1% |
| Group Consolidation | | | 0 | | | | | | | | | | | | | | | |
| AlzChem Group | 92,124 | 96,120 | 99,430 | 88,398 | 94,740 | 102,511 | 81,373 | 100,634 | 104,321 | | | | 9,582 | 9% | 94,740 | 104,321 | 9,582 | 10% |

| EBITDA | 2019 | | | | 2020 | | | | 2021 | | | | Deviation PY (Q1) | | YTD Q1 2021 | | Deviation PY (YOY) | |
|------------------------|---------------|---------------|---------------|--------------|---------------|---------------|---------------|---------------|---------------|----------|----------|----------|-------------------|------------|---------------|---------------|--------------------|------------|
| | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | | | PY T€ | Actual T€ | | |
| Basics & Intermediates | 1,038 | 628 | 3,220 | 360 | 1,903 | 2,485 | 2,006 | 2,587 | 2,791 | | | | 888 | 32% | 1,903 | 2,791 | 888 | 47% |
| Specialty Chemicals | 11,711 | 12,919 | 9,218 | 7,837 | 10,158 | 14,457 | 9,418 | 10,092 | 13,947 | | | | 3,789 | 27% | 10,158 | 13,947 | 3,789 | 37% |
| Other and Holding | 357 | 838 | 1,435 | 1,877 | 317 | 81 | 361 | 230 | 435 | | | | 118 | 27% | 317 | 435 | 118 | 37% |
| Group Consolidation | 125 | 239 | -309 | -1,414 | -63 | -201 | 202 | -227 | -451 | | | | -388 | 86% | -63 | -451 | -388 | 618% |
| AlzChem Group | 13,231 | 14,623 | 13,564 | 8,659 | 12,315 | 16,822 | 11,986 | 12,683 | 16,722 | | | | 4,407 | 26% | 12,315 | 16,722 | 4,407 | 36% |

EXECUTIVE TEAM

AlzChem Group AG



KLAUS ENGLMAIER, COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY Production, Engineering, Environment/Safety/Health/Quality, Technology

ANDREAS NIEDERMAIER, CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

DR. GEORG WEICHSELBAUMER, CSO


WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY Marketing, Sales, Innovation Management & Process Development, R&D, Product Safety and Approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



Fully Integrated Business Model (“Verbund” System)

Ability to adapt production to satisfy changing end market needs



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS

Growth of the population



Healthy aging



Sustainability





OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

| | MAIN PRODUCTS | DESCRIPTION | END-MARKETS |
|------------------------|------------------------|---|--|
| SPECIALTY CHEMICALS | CREAMINO | A feed additive for broilers and pigs | Feed additive |
| | Creapure® | Premium brand for creatine monohydrate as a food supplement in sports nutrition | Food supplements |
| | LIVADUR | Dietary supplement with pure creatine | Food supplements |
| | Dormex® | Plant growth regulator used in fruit production | Agriculture |
| | BREATHRU® S 301 | Additive for plant protection formulations | Agriculture |
| | Sitofex® | Plant growth regulator used in fruit production | Agriculture |
| | Alzogur® | Biocide for the prevention of diseases in animal production | Agriculture |
| | Silzot® HQ | Silicon nitride powder for ceramic applications | Ceramics |
| | Bioselect® | Highly purified form of guanidine hydrochloride salts | Pharmaceuticals / API |
| | Cyanamide | An organic compound widely used in agriculture and pharmaceuticals | Agriculture and pharmaceuticals |
| | DYHARD® | Hardeners and accelerators in powder, paste and liquid form | Hardener & Accelerator Systems for Composite Materials |
| | Thiourea | Various applications incl. flotation agents and pharmaceutical raw materials | Mining and pharmaceuticals |
| | Nitroguanidine | Intermediates for agrochemical products | Various |

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

| | MAIN PRODUCTS | DESCRIPTION | END-MARKETS |
|------------------------|--|---|-------------------------------|
| BASICS & INTERMEDIATES |  | Calcium carbide-based mixtures for hot metal desulphurization | Steel industry |
| | Guanidine Salts | Fuel for airbags, key production of the intermediate product | Automotive |
| | Dicyandiamide | Versatile intermediate in various markets including the pharmaceutical industry | Pharmaceutical Agriculture |
| | NITRALZ® | Business fields in color, agro and pharmaceutical applications | Pigments Pharmaceutical |
| | EMINEX | Reduction of Methan emissions during storage of manure | Agriculture |
| |  | Special calcium cyanamide multi-effect fertilizer | Agriculture |
| OTHER & HOLDING | Operation of the Trostberg Chemical Park (companies located at the site: AlzChem, BASF, Firmenich, Aramark, VIActiv, Degussa Bank) | | |
| | Site services | | |
| | Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments | | |


KEY SHARE DATA

Share Details as of May 4, 2021



| | |
|-----------------------|---|
| SHARES OUTSTANDING | 10,176,335 |
| LAST CLOSING PRICE | EUR 25.40 |
| MARKET CAPITALIZATION | EUR 258.5 m |
| TICKER | ACT |
| WKN | A2YNT3 |
| ISIN | DE000A2YNT30 |
| LISTING | Frankfurt Stock Exchange – Prime Standard |
| DESIGNATED SPONSOR | Baader Bank AG Oddo Seydler Bank AG |

SHAREHOLDER STRUCTURE



** Information regarding the free float in accordance with section 2.3 of the „Guide to the DAX Equity Indices“, as amended.*